Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.
about
Molecular pathogenesis and clinical management of Fanconi anemiaFanconi anemia and the cell cycle: new perspectives on aneuploidyCombining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaPreserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting.Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities.Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapyCurrent clinical management of Fanconi anemia.Sleeping Beauty-mediated correction of Fanconi anemia type C.Gene therapy for Fanconi anemia: one step closer to the clinic.Stem Cell Therapy for Fanconi Anemia.Current and emerging therapeutic strategies for Fanconi anemia.Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients.Alcohol, stem cells and cancer.Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage.Perspectives on gene therapy for Fanconi anemia
P2860
Q24621696-BB783B80-AD11-4971-9FB2-434CD62B4BEEQ27014905-69A40E9B-C838-4808-960B-AD2815C2ED28Q28537688-593B34E8-1FD3-464C-BA0C-1C29365CAB63Q30764873-4F7B0F7F-E2BF-4D0F-9308-5890A360AE93Q35086128-7509991F-9227-4B8E-B4FC-E77D6DF0D9A8Q36834114-A3B13091-803D-433C-819F-763A035ED279Q37366489-CE20C136-153D-442C-86BE-91E2C89BB89AQ38059251-5D81411C-35BB-474D-811C-0BF31F540629Q39505168-8AC30165-03B8-41BB-9372-558DE98E87B9Q42686916-0963AF33-B7B9-4A59-8627-B6B0DEBDA613Q45869566-DABAED71-CB1C-4252-A2C4-FCB7EA753D3DQ45871170-233F4F04-AAF2-4764-A294-835C207F42CFQ45871852-4D85F80E-F72C-473C-8C9D-E1AD0E6A9C46Q47107745-23F0491F-ED96-468C-B976-F4C32B8065B9Q47564275-DED1032F-0A9F-462F-B0CC-AC0B8967B141Q52335444-01833903-7B2E-4401-9CF6-CBA944B5CBC7Q57952326-95D6F548-B642-4C33-96A5-3A74AFDA0B38
P2860
Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Preclinical correction of huma ...... ty-modified lentiviral vector.
@ast
Preclinical correction of huma ...... ty-modified lentiviral vector.
@en
Preclinical correction of huma ...... ty-modified lentiviral vector.
@nl
type
label
Preclinical correction of huma ...... ty-modified lentiviral vector.
@ast
Preclinical correction of huma ...... ty-modified lentiviral vector.
@en
Preclinical correction of huma ...... ty-modified lentiviral vector.
@nl
prefLabel
Preclinical correction of huma ...... ty-modified lentiviral vector.
@ast
Preclinical correction of huma ...... ty-modified lentiviral vector.
@en
Preclinical correction of huma ...... ty-modified lentiviral vector.
@nl
P2093
P2860
P356
P1433
P1476
Preclinical correction of huma ...... ty-modified lentiviral vector.
@en
P2093
A Shimamura
G D Trobridge
J A Taylor
J E Wagner
P S Becker
P2860
P2888
P304
P356
10.1038/GT.2010.62
P577
2010-05-20T00:00:00Z
P5875
P6179
1049963999